ATRS - Antares Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.18
+0.06 (+2.83%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.12
Open2.13
Bid1.86 x 1000
Ask2.25 x 2000
Day's Range2.06 - 2.21
52 Week Range1.41 - 4.09
Volume3,399,887
Avg. Volume1,981,201
Market Cap340.97M
Beta0.11
PE Ratio (TTM)-18.63
EPS (TTM)-0.12
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.66
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Antares Pharma Receives Complete Response Letter From the FDA for XYOSTED™

    EWING, N.J., Oct. 20, 2017-- Antares Pharma, Inc. announced that today it has received a Complete Response Letter from the U.S. Food and Drug Administration regarding the New Drug Application for XYOSTED™ ...

  • PR Newswire4 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Antares Pharma, Inc. - ATRS

    NEW YORK , Oct. 18, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Antares Pharma, Inc. ("Antares" or the "Company") (NASDAQ: ATRS).   Such investors ...

  • Capital Cube5 days ago

    Antares Pharma, Inc. – Value Analysis (NASDAQ:ATRS) : October 17, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Antares Pharma, Inc. a score of 25. Our analysis is based on comparing Antares Pharma, Inc. with the following peers – ANI Pharmaceuticals, Inc., Becton, Dickinson and Company, Unilife Corporation, Retractable Technologies, Inc., West Pharmaceutical Services, Inc., Teva Pharmaceutical Industries Limited Sponsored ADR, Johnson & Johnson, Mylan ... Read more (Read more...)

  • Benzinga5 days ago

    Vetr Urges Buy On Antares Post-Correction

    The Vetr crowd on Monday upgraded its rating on Antares Pharma Inc (NASDAQ: ATRS ) from 3 stars (Hold), issued four days ago, to 5 stars (Strong Buy). Crowd sentiment at the time of the upgrade was unanimously ...

  • Antares Pharma, Inc. breached its 50 day moving average in a Bearish Manner : ATRS-US : October 16, 2017
    Capital Cube6 days ago

    Antares Pharma, Inc. breached its 50 day moving average in a Bearish Manner : ATRS-US : October 16, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Antares Pharma, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)

  • Why Antares Pharma Inc Plummeted Today
    Motley Fool9 days ago

    Why Antares Pharma Inc Plummeted Today

    An FDA rejection is coming for the drugmaker's testosterone replacement therapy Xyosted.

  • ACCESSWIRE9 days ago

    Today's Research Reports on Trending Tickers: Antares Pharma and Infinity Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / October 13, 2017 / Major Indexes pulled back on Thursday as investors digested earnings from JPMorgan Chase and Citigroup. The Dow Jones Industrial Average declined 0.14 percent ...

  • MarketWatch10 days ago

    Antares Pharma stock plunges more than 30% after FDA letter

    Antares Pharma Inc. announced Thursday that the U.S. Food and Drug Administration had found deficiencies in the drug Xyosted (testosterone enanthate) during its review process, the company said in a statement. ...

  • GlobeNewswire10 days ago

    Antares Pharma Provides XYOSTED™ Regulatory Update

    EWING, N.J., Oct. 12, 2017-- Antares Pharma, Inc. today announced that, on October 11, 2017, the Company received a letter from the U.S. Food and Drug Administration stating that, as part of their ongoing ...

  • ACCESSWIRE10 days ago

    Corporate News Blog - Antares Pharma Sells ZOMAJET(TM) Assets in a Potential $14.5 Million Deal

    Research Desk Line-up: IsoRay Post Earnings Coverage LONDON, UK / ACCESSWIRE / October 12, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Antares ...

  • GlobeNewswire13 days ago

    Antares Pharma Announces Sale of ZOMAJET™ Needle-Free Delivery System to Ferring Pharmaceuticals

    EWING, N.J., Oct. 10, 2017-- Antares Pharma, Inc. today announced that it has entered into a definitive asset purchase agreement to sell the worldwide rights, including certain fixed assets, for the ZOMAJET™ ...

  • Capital Cube13 days ago

    ETFs with exposure to Antares Pharma, Inc. : October 9, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Antares Pharma, Inc. Here are 5 ETFs with the largest exposure to ATRS-US. Comparing the performance and risk of Antares Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • TheStreet.com17 days ago

    Recent Tech Big-Cap Laggards Finally Gain Some Attention

    Money is flowing back into the FANG names and into Microsoft in particular while small-caps slow a bit.

  • TheStreet.com18 days ago

    Biotech Names Flexing Their Muscles

    There's action in Global Blood Therapeutics and Antares Pharma.

  • Antares Pharma, Inc. breached its 50 day moving average in a Bullish Manner : ATRS-US : September 27, 2017
    Capital Cube25 days ago

    Antares Pharma, Inc. breached its 50 day moving average in a Bullish Manner : ATRS-US : September 27, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Antares Pharma, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)

  • Capital Cube26 days ago

    ETFs with exposure to Antares Pharma, Inc. : September 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Antares Pharma, Inc. Here are 5 ETFs with the largest exposure to ATRS-US. Comparing the performance and risk of Antares Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • GlobeNewswirelast month

    Antares Pharma to Present at the Ladenburg Thalmann 2017 Healthcare Conference

    EWING, N.J., Sept. 20, 2017-- Antares Pharma, Inc. today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, ...

  • Is There Now An Opportunity In Antares Pharma Inc (ATRS)?
    Simply Wall St.last month

    Is There Now An Opportunity In Antares Pharma Inc (ATRS)?

    Antares Pharma Inc (NASDAQ:ATRS), a healthcare equipment and services company based in United States, received a lot of attention from a substantial price movement on the NasdaqCM in the overRead More...

  • ACCESSWIRElast month

    Antares: Positive Phase III Trials May Support the Case for Approval of Xyosted

    NEW YORK, NY / ACCESSWIRE / September 12, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • Capital Cubelast month

    ETFs with exposure to Antares Pharma, Inc. : September 12, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Antares Pharma, Inc. Here are 5 ETFs with the largest exposure to ATRS-US. Comparing the performance and risk of Antares Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Antares Pharma, Inc. :ATRS-US: Earnings Analysis: Q2, 2017 By the Numbers : September 8, 2017
    Capital Cubelast month

    Antares Pharma, Inc. :ATRS-US: Earnings Analysis: Q2, 2017 By the Numbers : September 8, 2017

    Categories: Yahoo FinanceGet free summary analysis Antares Pharma, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Antares Pharma, Inc. – ANI Pharmaceuticals, Inc., West Pharmaceutical Services, Inc., Becton, Dickinson and Company, Pfizer Inc., Eli Lilly and Company, Mylan N.V., Johnson & Johnson, Teva Pharmaceutical ... Read more (Read more...)

  • GlobeNewswire2 months ago

    Antares Pharma to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

    EWING, N.J., Sept. 05, 2017-- Antares Pharma, Inc. today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Rodman & Renshaw 19 th Annual Global Investment Conference ...

  • Antares Pharma, Inc. breached its 50 day moving average in a Bullish Manner : ATRS-US : August 25, 2017
    Capital Cube2 months ago

    Antares Pharma, Inc. breached its 50 day moving average in a Bullish Manner : ATRS-US : August 25, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Antares Pharma, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)

  • Capital Cube2 months ago

    Antares Pharma, Inc. – Value Analysis (NASDAQ:ATRS) : August 21, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Antares Pharma, Inc. a score of 25. Our analysis is based on comparing Antares Pharma, Inc. with the following peers – ANI Pharmaceuticals, Inc., Becton, Dickinson and Company, Unilife Corporation, Retractable Technologies, Inc., West Pharmaceutical Services, Inc., Teva Pharmaceutical Industries Limited Sponsored ADR, Johnson & Johnson, Mylan ... Read more (Read more...)

  • Zacks Small Cap Research2 months ago

    ATRS: Milestones Continue to Align for Multiple 2018 Launches

    Antares Pharma, Inc. (ATRS) announced second quarter results on August 8, 2017, achieving 10% revenue growth and a loss of ($0.02) per share.  Second quarter revenues of $13.4 million compare to our $14.1 million estimate, which had anticipated higher product sales.  Net loss of ($0.02) per share was ahead of our ($0.03) estimate.  Gross margin was up 18 percentage points to 58.1% compared to 40.2% in 2Q:16 due to a greater proportion of higher margin non-product sales, increased license revenue and better margins on Otrexup and sumatriptan. The second quarter provided evidence of increasing market share for Antares’ most important products, with the sumatriptan auto injector achieving 26% market share in 2Q:17, up from 21% in 1Q:17.  The most recent weekly data ending July 21 indicated a market share of 29%, illustrating continued share gains and the benefit of Teva’s relationships with Walgreens and CVS.  Otrexup prescriptions were up 16% sequentially and 14% over the prior year with total sales up 3.0%, however average price declined as Antares renegotiated some agreements to improve formulary coverage.